吉非替尼对晚期非小细胞肺癌患者生活质量的影响  

The effect of gefitinib on the quality of life in patients with advanced non-small cell lung cancer

作　　者：邹燕梅[1] 熊华[1] 于世英[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤中心,湖北武汉430030

出　　处：《中国癌症杂志》2008年第12期925-928,共4页China Oncology

摘　　要：背景与目的:提高晚期非小细胞肺癌患者的生活质量是肿瘤学者关注的问题之一。吉非替尼已广泛用于治疗晚期非小细胞肺癌。本研究探讨吉非替尼对晚期非小细胞肺癌患者生活质量的影响。方法:70例晚期非小细胞肺癌患者,每日口服吉非替尼250mg,直至病情进展或出现严重不良反应。采用欧洲癌症研究和治疗组织(European Organization for Research and Treatment of Cancer,EORTC)简体中文版EORTC QLQ-C30和QLQ-LC13问卷对治疗前、后症状和生活质量的改变进行评价。结果:58例患者(85.3%)完成了问卷调查。治疗前和治疗8周后患者5种功能状态(躯体、角色、情感、认知、社会)的均值分别为52和63,49和56,64和68,60和65,52和61,整体生活质量评分的均值分别为53和60,差异有显著性(P<0.05);治疗前、后全身症状(乏力、食欲不振)的均值分别为61和58,52和48,肺癌相关症状(呼吸困难、咳嗽、咯血、胸痛)的均值分别为55和49,54和47,28和27,29和25,其中乏力、呼吸困难、咳嗽、胸痛的差异有显著性(P<0.05)。治疗后5种功能状态和整体生活质量的有效率均超过50%,全身症状和肺癌相关症状的有效率均超过40%。症状和生活质量的改善与疾病控制相一致。生活质量改善者生存延长。结论:吉非替尼明显改善晚期非小细胞肺癌患者的症状和生活质量。Background and purpose： To improve the quality of life of patients with advanced non-small cell lung cancer is one of the problems which the oncologists have to be aware of. Gefitinib has been used to treat advanced non-small cell lung cancer. We studied the effect of gefitinib in the improvement of quality of life of patients with advanced non-small cell lung cancer. Methods： There were 70 patients with advanced non-small cell lung cancer treated in our cancer center. One oral gefitinib tablet （250 mg） was administered every day without interruption unless disease progression or unacceptable toxicity occurred. The impact of treatment on disease-related symptoms and quality of life （QoL） were evaluated with the Chinese versions of European Organization for Research and Treatment of Cancer Quality of Life Questionnaires （EORTC QLQ-C30 and QLQ-LC13）. Results： 58 patients finished the questionnaires. The mean scores of five functional scales （physical, role, emotional cognitional and social） were 63, 56, 68, 65, 61 respectively after eight weeks of treatment, compared to 52, 49, 64, 60, 52 respectively before treatment, and the mean score of global QoL after and before treatment were 60 and 53 respectively. There were statistical differences in five functional scales and global QoL （P〈0.05）. The mean scores of main general symptoms （fatigue and appetite loss） were 58 and 48 respectively after eight weeks of treatment, compared to which 61 and 52 respectively before treatment, and the mean scores of disease-related symptoms （dyspnoea, coughing, empsyxis, pain in chest） were 49, 47, 27, 25 respectively after eight weeks of treatment, which were 55, 54, 28, 29 respectively before treatment. There were statistical differences in fatigue, dyspnoea, cough and pain in chest（P〈0.05）. All of the response rate of five functions and global QoL were more than 50% after gefitinib treatment. The response rate of main general symptoms and diseaserelated symptoms were all more than 40%. Bot

关 键 词：非小细胞肺癌 生活质量 吉非替尼 

分 类 号：R734.2[医药卫生—肿瘤]